Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 772 Jul 12 – Oct 9, 2026
- Disclosed funding
- $67.1B 615 disclosed amounts
- Median round
- $22.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| E EubricsCompany profile An AI sales enablement platform helps teams rehearse customer conversations, get live guidance and improve from call analytics. An AI sales enablement platform helps teams rehearse customer conversations, get live guidance and improve from call analytics. | Undisclosed | Pre-seed | AI | United States | Investors | |
| VH Verily HealthCompany profile An AI-native precision-health platform organizes complex health data for research, care and personalized health services. An AI-native precision-health platform organizes complex health data for research, care and personalized health services. | Undisclosed | March financing extensionUndisclosed | Healthtech | United States | Investors | |
| M Moneyball.aiCompany profile AI deal-team software helps boutique investment banks match deals to investors and manage outreach through closing. AI deal-team software helps boutique investment banks match deals to investors and manage outreach through closing. | Undisclosed | Pre-seed | Fintech | United States | Investors | |
| V VideoGenCompany profile AI video-creation software that helps creators, businesses and teams turn briefs or source media into editable, localized videos. AI video-creation software that helps creators, businesses and teams turn briefs or source media into editable, localized videos. | $3.3M | Seed | AI | United States | Investors | |
| L LatitudeCompany profile Provides payment infrastructure connecting stablecoins with local currencies and payment networks. Provides payment infrastructure connecting stablecoins with local currencies and payment networks. | $35M | Series A | Fintech | United States | Investors | |
| SO Solstice OncologyCompany profile A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment. A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment. | $225M | Series A | Biotech | United States | Investors | |
| CC Celero CommunicationsCompany profile Celero develops coherent digital signal processors and analog technology for optical links that connect AI accelerators and data centers. Its validated 2nm silicon architecture is designed to move more data across scale-up, scale-out and data-center links with lower power and a path from 1.6T to next-generation 3.2T connectivity. Celero develops coherent digital signal processors and analog technology for optical links that connect AI accelerators and data centers. Its validated 2nm silicon architecture is designed to move more data across scale-up, scale-out and data-center links with lower power and a path from 1.6T to next-generation 3.2T connectivity. | $275M | Series CSeries C+ | Hardware | United States | Investors | |
| L LightsageCompany profile An agent-led growth platform measures whether AI agents can discover, evaluate and successfully use a company’s software. An agent-led growth platform measures whether AI agents can discover, evaluate and successfully use a company’s software. | $4M | FundingUndisclosed | AI | United States | Investors | |
| CI ClaimQI, Inc.Company profile Claims-intelligence software that helps health plans review and prevent improper payments against coverage rules and policy language. Claims-intelligence software that helps health plans review and prevent improper payments against coverage rules and policy language. | ~$500K | Seed | Healthtech | United States | Investors | |
| ET Encoded Therapeutics Inc.Company profile Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome. Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome. | $275M | Series FSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 12, 2026
- 1Y Combinator (YC)
Nous Research, Santé, Vitalize
55rounds3led - 2Andreessen Horowitz (a16z)
TypeSafe AI, Arena, Vesta
40rounds15led - 3Khosla Ventures
Arena, Vinci, Conway Research
25rounds5led - 4Sequoia Capital
TypeSafe AI, Mecka, Healthleap
23rounds5led - 5Insight Partners
Stuut, Hestus, Inc., Quartermaster
21rounds9led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.